gonadotropin-releasing hormone antagonists + human menopausal gonadotropin

This is a combination therapy used primarily in assisted reproductive technology (ART), especially in in vitro fertilization (IVF) protocols. It combines gonadotropin-releasing hormone (GnRH) antagonists with human menopausal gonadotropin (hMG). GnRH antagonists are synthetic analogs that competitively bind to GnRH receptors on pituitary gonadotrophs, leading to immediate and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby preventing premature ovulation[2][6][8][10]. Human menopausal gonadotropin is a purified preparation containing both FSH and LH activity, used to stimulate ovarian follicular development. The combination aims to optimize controlled ovarian stimulation by suppressing endogenous LH surges while providing exogenous FSH/LH support for follicle growth[1][3]. This regimen is commonly employed during IVF cycles.